Titlebook: Breast Cancer; A Guide to Detection Michael H. Torosian Book 2002 Springer Science+Business Media New York 2002 biopsy.carcinoma.classifica

非實(shí)體

一夫一妻制

Male Breast Cancerat the conclusions drawn from these studies have been largely consistent. Breast cancer treatment in men has been mostly guided by studies in women. These guidelines have been established owing to the similarities of disease behavior between the two genders. Because of the consistency of conclusions

Consequence

Oncogenes in the Development of Breast Cancertumor development and progression. The Human Genome Project will increase knowledge of the molecular determinants of breast cancer suddenly and drastically. The utilization of this knowledge in the clinic, however, will lag by a few years. It is thus important to consider the present state of knowle

玉米

Primary Chemotherapy chemotherapy, neoadjuvant chemotherapy, induction chemotherapy, and upfront chemotherapy. Beginning in the early 1970s, primary chemotherapy has been explored to improve local control and survival in women with large breast tumors or inflammatory breast cancer. Primary chemotherapy produced regress

羊欄

Axillary Adenopathy as the Initial Presentation of Breast Cancer 1907 .. These occult primary cancers are staged as TONI, stage II breast cancer when thorough clinical and radiologic investigations do not reveal the presence of a primary breast tumor. The reported incidence of this phenomenon ranges from 0.3 to 0.8% .. The mean age at presentation is approximate

極大的痛苦

土坯

growth-factor

Breast Biopsy Techniques. In the past, all women requiring breast biopsies underwent single-stage procedures under general anesthesia, and the decision to proceed with definitive cancer therapy (which was always a mastectomy) was made intraoperatively, based on frozen section evaluation of the excised palpable mass.

歡騰

irradicable

Chemotherapy in Breast Cancernerstones of treatment and has evolved over the past 20 years. Chemotherapy has shown benefit in both early and advanced disease. The decision of when to administer cytotoxic therapy and which agents to utilize is often a complex and challenging dilemma for clinicians and their patients.